Survodutid
Mechanism of action
What Survodutid does in the body — step by step.
Survodutide is a dual agonist at glucagon and GLP-1 receptors.
The GLP-1 component promotes glucose-dependent insulin secretion and satiety, while the glucagon component is intended to increase energy expenditure and hepatic fat metabolism.
The aim of this combination is weight reduction beyond that of pure GLP-1 agonists, together with a favourable effect on the liver.
Research status
How far along is the evidence?
Known risks
Without human data, safety statements are limited. What is known:
Cited studies
Chronological — links lead to the source.
Frequently asked questions
What is Survodutid?+
Survodutide is a dual agonist at glucagon and GLP-1 receptors.
What type of peptide is Survodutid?+
Survodutid belongs to the GLP-1 analog class.
What is Survodutid used for?+
In research, Survodutid has primarily been investigated in the context of: Metabolism. These are research findings (evidence: early clinical studies), not proven benefits in humans and not a usage recommendation.
Is Survodutid legal in Germany?+
Survodutid is not approved as a medicine in Germany. Obtaining it outside clinical studies is legally problematic.
Is Survodutid FDA-approved / legal in the US?+
No. Survodutid is not FDA-approved as a drug in the US; it is mostly sold as a research chemical and not for human consumption.
Is Survodutid legal in Canada?+
No. Survodutid is not authorized by Health Canada and not intended for human consumption.
Where can I buy Survodutid?+
Peptica sells nothing and names no sources. Survodutid is "not approved" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.
What is the dosage of Survodutid?+
Peptica publishes no dosing. There are no approved dosing guidelines for Survodutid; figures circulating online stem from animal studies or anecdote, not from validated human protocols. This is not medical advice.
Is Survodutid banned in sport (WADA)?+
Survodutid is currently not on the WADA Prohibited List.
What are the known risks of Survodutid?+
Documented risks include: Safety profile not conclusively established — no completed Phase III data; Gastrointestinal side effects (nausea, vomiting, diarrhoea) common. This is not a complete safety assessment and not medical advice — see the risks section for the full list.
How well researched is Survodutid?+
The evidence is classified as “early clinical studies”. 2 studies are cited on this page.
What is the molecular weight of Survodutid?+
Survodutid has a molar mass of about 4232 Da, with a plasma half-life of ~6–7 days (once weekly).
Which peptides are related to Survodutid?+
Closely related entries: Retatrutid, Tirzepatid, Semaglutid, Mazdutid. A direct side-by-side comparison is available via the compare function.
Dossier
Legal · Structure · Sources.
Survodutide does not yet have market approval and is in Phase III studies. Obtaining it as a research chemical outside clinical studies is illegal and carries considerable safety risks.
Legal status varies by country and can change. This is not legal advice.
Methodology: Peptica compiles publicly available studies and regulatory information and assigns each statement an evidence level. Not medical advice. No warranty.